News

Get the latest from Biologics

We invite you to learn more about our work. Check out our organization’s recent news, and browse our press releases to see what we’ve been doing. You can also check out upcoming events in which we’ll be participating or read more about our how we give back to our community.

TAVALISSE (fostamatinib disodium hexahydrate) Approved by FDA, Available for Order at Biologics, Inc.

CARY, N.C. (May 29, 2018) —Biologics, Inc., a McKesson Specialty Health oncology, neurology and complex care pharmacy services company, announced today that it has been selected by Rigel Pharmaceuticals, Inc. to be in the limited distribution network for TAVALISSETM (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase(SYK) inhibitor for the treatment of thrombocytopenia in adult patients with chronic immun… Read More

ERLEADA (apalutamide), the first FDA-approved treatment for non-metastatic, castration-resistant prostate cancer, available for order at Biologics, Inc.

CARY, N.C. (February 21, 2018) —Biologics, Inc., a McKesson Specialty Health oncology and complex care pharmacy services company, has been selected by the Janssen Pharmaceutical Companies of Johnson & Johnson1 to be in the limited distribution network for ERLEADA™ (apalutamide), the first FDA-approved treatment for non-metastatic, castration-resistant prostate cancer (NM-CRPC). The addition of this critica… Read More

Biologics, Inc. Joins MedImpact Direct Specialty Program’s Specialty Pharmacy Network

CARY, N.C. (January 25, 2018) —Biologics, Inc., a McKesson Specialty Health oncology and complex care pharmacy services company, is now contracted with MedImpact Healthcare Systems, Inc. (“MedImpact”) to dispense specialty prescriptions under the MedImpact Direct Specialty program. “We are pleased to provide pharmacy services to members on behalf of the MedImpact Direct Specialty program,” said… Read More

McKesson Specialty Pharmacy Solutions Announces New Role for Key Executive

CARY, NC — November 2, 2017 — McKesson Specialty Pharmacy Solutions is pleased to announce Paula Bickley as Vice President, Market Access. In this new role, Paula will be tasked with expanding payer contracts to provide broader access to treatment for specialty pharmacy patients. In doing so, Paula will focus heavily on identifying solutions to… Read More

CALQUENCE® (acalabrutinib) Approved for Previously-Treated Mantle Cell Lymphoma, Available for Order at Biologics, Inc.

CARY, N.C. (November 1, 2017) —Biologics, Inc., a McKesson Specialty Health oncology pharmacy services company, has been selected by AstraZeneca to be in the limited distribution network for CALQUENCE® (acalabrutinib), a new oral treatment for adult patients with mantle cell lymphoma (MCL) who have received at least one prior therapy. CALQUENCE is a highly selectiv… Read More

VERZENIO (abemaciclib) Approved for Treatment of Metastatic Breast Cancer, Available for Order at Biologics, Inc.

CARY, N.C. (October 10, 2017) —Biologics, Inc., a McKesson Specialty Health oncology pharmacy services company, has been selected by Eli Lilly and Company to be in the limited distribution network for VERZENIOTM (abemaciclib), Eli Lilly’s first oral oncolytic indicated for metastatic breast cancer. Approved by the U.S. Food and Drug Administration (FDA) on September 28,… Read More

BESPONSA® (inotuzumab ozogamicin) Approved for Treatment of Adult Relapsed or Refractory B-cell Precursor Acute Lymphoblastic Leukemia, available for order at Biologics, Inc.

CARY, N.C. (August 22, 2017) —Biologics, Inc., a McKesson Specialty Health oncology pharmacy services company, announced today it has been selected by Pfizer, Inc. to be a specialty pharmacy provider for BESPONSA® (inotuzumab ozogamicin), a promising new IV therapy for adult patients with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL). Approved by t… Read More

NERLYNX (neratinib) Tablets Approved for HER2+ Breast Cancer in the Extended Adjuvant Setting

CARY, N.C. (July 21, 2017) —Biologics, Inc., a McKesson Specialty Health oncology pharmacy services company, announced today it has been selected to be in the limited distribution network for Puma Biotechnology, Inc.’s new product, NERLYNX, a kinase inhibitor approved by the U.S. Food and Drug Administration (FDA). NERLYNX is indicated for the extended adjuvant treatment… Read More

Biologics, Inc. Earns Prestigious URAC Accreditation for Specialty Pharmacy

Rigorous accreditation process helps ensure high-quality care, ongoing process improvement and optimal outcomes CARY, N.C. (June 27, 2017) —Biologics, Inc., a McKesson Specialty Health oncology pharmacy services company, has achieved Specialty Pharmacy accreditation from URAC, the healthcare industry’s leading certification and accreditation organization that evaluates quality standards. The independent non-profit organization promotes quality by ensuring… Read More

Biologics’ Patient Access Services Team Procures more than $44 Million in Co-pay Assistance for Cancer Patients in 2016

CARY, N.C. (May 24, 2017) —Biologics, Inc., a McKesson Specialty Health oncology pharmacy services company, secured more than $44 million in co-pay assistance in 2016 for commercial patients in need of oral chemotherapy drugs, easing the financial burden for these patients battling cancer. The Biologics’ Patient Access Services team also referred more than 38,000 unique patients to… Read More